Health Condition 1: K746- Other and unspecified cirrhosis ofliver Health Condition 2: N29- Other disorders of kidney and ureter in diseases classified elsewhere
Conditions
Interventions
Intervention1: Continuous terlipressin infusion and Norepinephrine: 1. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if targ
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. ACLF as per APASL 2. AKI according to KDIGO Criteria 3. septic shock requiring norepinephrine (less tha 0.05mcg per kg per min).
Exclusion criteria
Exclusion criteria: 1. Septic shock requiring 2 vasopressors (Norephinephrine requirement more than 0.05mcg/kg/min) 2. Symptomatic cardiopulmonary disease 3. Chronic kidney disease 4. Peripheral vascular disease 5. Hepatocellular carcinoma outside Milan criteria 6. Prior use of terlipressin in last 48 hours 7. Patients with hypovolemic or hemorrhagic shock 8. Patients already meeting criteria for dialysis or with history of dialysis in last 7 days 9. Intrinsic kidney disease, Acute tubular necrosis with urinary output less than 400 ml /day or obstructive uropathy 10. History of immunosuppressive drugs 11. Pregnancy 12. Human immunodeficiency virus 1 and 2 13. Portal vein thrombus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients developing 1 stage improvement in Acute kidney injury stage with resolution of shock at day 4 in both groupsTimepoint: Day 4 | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome (resolution, persistence or progreession) of acute kidney injury at day 4,7Timepoint: Day 4 & 7;Incidence of adverse events in both groupsTimepoint: 1 year;Need of renal replacement therapy at day 7Timepoint: Day 7;Duration of ICU and hospital stayTimepoint: 1 year;MortalityTimepoint: Day 7 and 28 | — |
Countries
India
Contacts
Public ContactDr Rakhi Maiwall
Institute of Liver and Biliary Sciences
Outcome results
None listed